Table 1.
Demographics and Baseline Characteristics of Study Subjects
| Characteristic | Evaluable subjects |
|---|---|
| N = 10 | |
| Age (years) | |
| Median (IQR) | 22.5 (22, 40) |
| Sex | |
| Female | 7 (70 %) |
| Male | 3 (30 %) |
| Race | |
| White | 5 (50 %) |
| Black or African American | 3 (30 %) |
| Asian | 1 (10 %) |
| Multi-Racial | 1 (10 %) |
| Body Mass Index (kg/m2) | |
| Median (IQR) | 23.0 (21.4, 24.3) |
| FEV1, Baseline (day 0) | |
| Median (IQR) | 3.09 (2.78, 3.62) |
| FEV1 % Predicted, Baseline (day 0) | |
| Mean (SD) | 95.1 (11.6) |
| PC20, Baseline (screening, mg/m2) | |
| Median (IQR) | 1.79 (0.49, 3.62) |
| Asthma Medications (baseline) | |
| Short Acting Beta Agonist, inhaled | 9 (90 %) |
| Long Acting Beta Agonist/Glucocorticoid, inhaled | 2 (20 %) |
| Glucocorticoid, inhaled | 1 (10 %) |
| Leukotriene-receptor antagonist | 2 (20 %) |
Abbreviations: IQR interquartile range, FEV1 forced expiratory volume in 1 second, SD standard deviation, PC 20 provocative concentration producing a 20 % decline (PC20)